GlassScriptPhysician profile
Pegah Akbari
NPI 1972164788
$3,182.94
in general payments reported to CMS, 2019-2025
26 companies · $866 in 2025
The $866 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.84 · 2020: $135 · 2021: $305 · 2022: $182 · 2023: $883 · 2024: $751 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $645.06 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $568.41 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $262.11 | 2022-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $230.93 | 2020-2021 | |
| Abbvie INC. | $176.56 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $174.03 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $155.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $133.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $106.56 | 2021 | |
| Neurocrine Biosciences, INC. | $102.08 | 2021 | |
| Pfizer INC. | $94.42 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.07 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.46 | 2022-2024 | Stiolto Respimat, Jardiance |
| Sumitomo Pharma America, INC. | $56.80 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $37.92 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $37.31 | 2023-2024 | Immunocap |
| Novartis Pharmaceuticals Corporation | $37.06 | 2022-2023 | |
| Axsome Therapeutics, INC. | $34.16 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $28.82 | 2025 | Inspire |
| Vertex Pharmaceuticals Incorporated | $27.21 | 2025 | |
| Lundbeck LLC | $24.01 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $22.40 | 2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $21.95 | 2024 | Watchman Flx |
| Vanda Pharmaceuticals INC. | $18.98 | 2025 | Fanapt |
| Astellas Pharma US INC | $12.82 | 2023 | Myrbetriq |
| Endogastric Solutions, INC | $9.75 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pegah Akbari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.